VK-1727 is a selective EBNA1 inhibitor that suppresses EBV-positive cell proliferation and metabolism by blocking EBNA1-DNA binding, showing specificity by sparing EBV-negative cells. It is a key research tool for investigating EBNA1s role in diseases like multiple sclerosis, with utility in both in vitro and in vivo experimental models.
